Home | Pharmaceutical Outsourcing - The Journal of Pharmaceutical & Biopharmaceutical Contract Services

Close Ad ☒

Show Ad

Horizon Lines: A Quarterly Review of NDAs – October- December 2025
This quarterly review of New Drug Applications contains data for applications approved for the first time during the last quarter of 2025, which includes New Molecular Entities (NMEs) and new biologics. A total of 40 applications were approved by the FDA during these three months. read more
Safely Scaling Highly Potent API manufacturing
Ever more drug developers are searching for CDMOs with contamination-limiting capabilities. But how can they know which have these high-potency credentials? read more
Five Steps to Smooth Agentic AI Adoption
In agentic AI-enabled labs, AI goes from individual, one-off applications to comprehensive workflow orchestration. read more
Horizon Lines: A Quarterly Review of NDAs – January-March, 2026
The NDAs approved during the first quarter of 2026 have been divided into the dosage forms Injection, Tablets, Capsules, Oral solution, Gas, and other. read more

Clinical Trials - Transforming Drug Development
Transforming Drug Development: Accelerating Clinical Trials through Patient-Centric Innovations and Technological Breakthroughs Watch Now

Clinilabs Names Laura Shannon CEO; Founder Gary Zammit Becomes Executive Chair
Tuesday, August 18, 2026
Clinilabs has appointed biopharma executive Laura Shannon as chief executive officer and promoted founder Gary Zammit, Ph.D., to executive chairperson... read more
Genprex Selects U.S. CDMO to Scale Diabetes Gene Therapy Manufacturing
Tuesday, August 18, 2026
Genprex has selected a U.S.-based contract development and manufacturing organization to scale production of its investigational diabetes gene therapy... read more
Lonza Launches Rapid Custom Media Prototyping Service for Cell Culture
Tuesday, August 18, 2026
Lonza has launched a rapid custom media prototyping service designed to help life sciences customers accelerate early-stage development of cell ... read more
Ryvu Launches Keelira to Support Early Oncology Trials in Europe
Tuesday, August 18, 2026
Ryvu Therapeutics has launched Keelira, a dedicated early clinical development services business designed to help biotechnology and pharmaceutical ... read more
Eurofins CDMO Alphora Expands High-Potency Development Capacity in Canada
Friday, August 14, 2026
Eurofins CDMO Alphora has expanded its kilolab and high-potency active pharmaceutical ingredient development and manufacturing capabilities in ... read more